vs

Side-by-side financial comparison of IMMERSION CORP (IMMR) and Indivior Pharmaceuticals, Inc. (INDV). Click either name above to swap in a different company.

IMMERSION CORP is the larger business by last-quarter revenue ($372.9M vs $357.0M, roughly 1.0× Indivior Pharmaceuticals, Inc.). Indivior Pharmaceuticals, Inc. runs the higher net margin — 28.9% vs -4.6%, a 33.4% gap on every dollar of revenue.

Immersion Corporation is an Aventura, Florida based developer and licensor of touch feedback technology, also known as haptic technology. Immersion Corporation has been accused of being a patent troll. Founded in 1993 by Louis Rosenberg, it is currently headed by lawyer Francis Jose, who serves as both chief executive officer and general counsel.

Indivior is a global specialty pharmaceutical company dedicated to developing and commercializing evidence-based treatments for substance use disorders such as opioid use disorder and alcohol dependence, as well as related mental health conditions. Its primary operating markets are North America and Europe, with a portfolio of approved therapies targeting unmet medical needs for underserved patient groups.

IMMR vs INDV — Head-to-Head

Bigger by revenue
IMMR
IMMR
1.0× larger
IMMR
$372.9M
$357.0M
INDV
Higher net margin
INDV
INDV
33.4% more per $
INDV
28.9%
-4.6%
IMMR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IMMR
IMMR
INDV
INDV
Revenue
$372.9M
$357.0M
Net Profit
$-17.0M
$103.0M
Gross Margin
82.1%
Operating Margin
-2.8%
22.7%
Net Margin
-4.6%
28.9%
Revenue YoY
750.4%
Net Profit YoY
-191.3%
390.5%
EPS (diluted)
$-0.57
$0.79

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IMMR
IMMR
INDV
INDV
Q4 25
$357.0M
Q3 25
$314.0M
Q2 25
$372.9M
$302.0M
Q1 25
$471.3M
$266.0M
Q4 24
$616.2M
Q3 24
$307.0M
Q2 24
$95.5M
$299.0M
Q1 24
$43.8M
Net Profit
IMMR
IMMR
INDV
INDV
Q4 25
$103.0M
Q3 25
$42.0M
Q2 25
$-17.0M
$18.0M
Q1 25
$24.1M
$47.0M
Q4 24
$30.8M
Q3 24
$22.0M
Q2 24
$26.4M
$-97.0M
Q1 24
$18.7M
Gross Margin
IMMR
IMMR
INDV
INDV
Q4 25
82.1%
Q3 25
73.2%
Q2 25
82.8%
Q1 25
83.1%
Q4 24
Q3 24
78.5%
Q2 24
73.6%
Q1 24
Operating Margin
IMMR
IMMR
INDV
INDV
Q4 25
22.7%
Q3 25
13.7%
Q2 25
-2.8%
23.8%
Q1 25
7.5%
24.8%
Q4 24
11.4%
Q3 24
11.4%
Q2 24
23.7%
-39.5%
Q1 24
37.9%
Net Margin
IMMR
IMMR
INDV
INDV
Q4 25
28.9%
Q3 25
13.4%
Q2 25
-4.6%
6.0%
Q1 25
5.1%
17.7%
Q4 24
5.0%
Q3 24
7.2%
Q2 24
27.7%
-32.4%
Q1 24
42.5%
EPS (diluted)
IMMR
IMMR
INDV
INDV
Q4 25
$0.79
Q3 25
$0.33
Q2 25
$-0.57
$0.14
Q1 25
$0.73
$0.38
Q4 24
$0.93
Q3 24
$0.16
Q2 24
$0.81
$-0.72
Q1 24
$0.59

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IMMR
IMMR
INDV
INDV
Cash + ST InvestmentsLiquidity on hand
$161.4M
$195.0M
Total DebtLower is stronger
$103.1M
Stockholders' EquityBook value
$298.1M
$-98.0M
Total Assets
$1.1B
$1.2B
Debt / EquityLower = less leverage
0.35×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IMMR
IMMR
INDV
INDV
Q4 25
$195.0M
Q3 25
$445.0M
Q2 25
$161.4M
$510.0M
Q1 25
$153.9M
$373.0M
Q4 24
$159.3M
Q3 24
Q2 24
$133.4M
Q1 24
$179.1M
Total Debt
IMMR
IMMR
INDV
INDV
Q4 25
Q3 25
Q2 25
$103.1M
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
IMMR
IMMR
INDV
INDV
Q4 25
$-98.0M
Q3 25
$-207.0M
Q2 25
$298.1M
$-257.0M
Q1 25
$317.9M
$-285.0M
Q4 24
$305.5M
Q3 24
$-310.0M
Q2 24
$273.4M
$-281.0M
Q1 24
$201.5M
Total Assets
IMMR
IMMR
INDV
INDV
Q4 25
$1.2B
Q3 25
$1.4B
Q2 25
$1.1B
$1.5B
Q1 25
$1.4B
$1.4B
Q4 24
$1.4B
Q3 24
Q2 24
$1.2B
Q1 24
$244.7M
Debt / Equity
IMMR
IMMR
INDV
INDV
Q4 25
Q3 25
Q2 25
0.35×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IMMR
IMMR
INDV
INDV
Operating Cash FlowLast quarter
$-221.0M
Free Cash FlowOCF − Capex
$-245.0M
FCF MarginFCF / Revenue
-68.6%
Capex IntensityCapex / Revenue
6.7%
Cash ConversionOCF / Net Profit
-2.15×
TTM Free Cash FlowTrailing 4 quarters
$-93.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IMMR
IMMR
INDV
INDV
Q4 25
$-221.0M
Q3 25
$-39.0M
Q2 25
$158.0M
Q1 25
$-43.7M
$75.0M
Q4 24
Q3 24
$2.0M
Q2 24
$-85.9M
$88.0M
Q1 24
$29.9M
Free Cash Flow
IMMR
IMMR
INDV
INDV
Q4 25
$-245.0M
Q3 25
$-59.0M
Q2 25
$141.0M
Q1 25
$-46.2M
$70.0M
Q4 24
Q3 24
$-5.0M
Q2 24
$84.0M
Q1 24
FCF Margin
IMMR
IMMR
INDV
INDV
Q4 25
-68.6%
Q3 25
-18.8%
Q2 25
46.7%
Q1 25
-9.8%
26.3%
Q4 24
Q3 24
-1.6%
Q2 24
28.1%
Q1 24
Capex Intensity
IMMR
IMMR
INDV
INDV
Q4 25
6.7%
Q3 25
6.4%
Q2 25
5.6%
Q1 25
0.5%
1.9%
Q4 24
Q3 24
2.3%
Q2 24
1.3%
Q1 24
Cash Conversion
IMMR
IMMR
INDV
INDV
Q4 25
-2.15×
Q3 25
-0.93×
Q2 25
8.78×
Q1 25
-1.82×
1.60×
Q4 24
Q3 24
0.09×
Q2 24
-3.25×
Q1 24
1.60×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IMMR
IMMR

Course Material Sale$150.9M40%
General Merchandise Sale$138.0M37%
Rental Services$51.8M14%
Services And Other Revenue$25.6M7%
Per Unit Royalties$1.8M0%

INDV
INDV

Sublocade$233.0M65%
Sublingual And Other$69.0M19%
Other$49.0M14%
Perseris$6.0M2%

Related Comparisons